Technical Data
| Formula | C46H64N14O12S2.C2H4O2 |
||||||
| Molecular Weight | 1129.27 | CAS No. | 62288-83-9 | ||||
| Solubility (25°C)* | In vitro | DMSO | 100 mg/mL (88.55 mM) | ||||
| Water | 100 mg/mL (88.55 mM) | ||||||
| Ethanol | 100 mg/mL (88.55 mM) | ||||||
| In Vivo (Add solvents to the product individually and in order.) |
|
||||||
|
* <1 mg/ml means slightly soluble or insoluble. * Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations. * Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.) |
|||||||
Preparing Stock Solutions
Biological Activity
| Description | Desmopressin is a synthetic octapeptide, and an analogue of human hormone arginine vasopressin with antidiuretic and coagulant activities. It is a selective agonist for the vasopressin V2 receptor (V2R). | |||||
|---|---|---|---|---|---|---|
| In vitro | Desmopressin (DDAVP) is a selective agonist for the Vasopressin V2 receptor (V2R), which is coupled to cAMP-dependent signalling. DDAVP induces cAMP-dependent eNOS activation via Ser1177 phosphorylation. DDAVP (at doses ranging from 100 ng/ml to 1 μg/ml) exerts a modest but significant antiproliferative effect on cultured CT-26 and Colo-205 cells. | |||||
| In Vivo | In vivo, DDAVP (2 μg/kg) reduces accumulation of ascites and formation of intestinal tumour nodules in mice intraperitoneally inoculated with CT-26 cells. Perioperative administration of DDAVP significantly inhibits tumour progression in animals surgically implanted in the spleen with CT-26 cells, and causes some reduction in liver metastasis. DDAVP is able to inhibit lung colonisation by blood-borne breast cancer cells in an experimental murine model. It dramatically reduces lymph node and lung metastasis in a model of mammary tumour manipulation and surgical excision in mice when administered perioperatively, and also exerts anti-tumour effects in combination with chemotherapy. DDAVP increases the plasma levels of coagulation factor VIII, von Willebrand factor (VWF) and tissue-type plasminogen activator, and also enhances platelet adhesion to the vessel wall. | |||||
| Density | 95.0~105.0% | |||||
Protocol (from reference)
| Cell Assay: |
|
|---|---|
| Animal Study: |
|
References
|
RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.
SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.
NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.